NasdaqCM USD

Akebia Therapeutics, Inc. (AKBA)

0.7258 +0.0174 (+2.46%)

At close: 4:00:02 PM EST

0.7258 -0.0006 (-0.08%)

After hours: 4:02:01 PM EST

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire 5d ago

AKBA
+2.46%
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

GlobeNewswire 27d ago

AKBA
+2.46%
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

GlobeNewswire 28d ago

AKBA
+2.46%
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

GlobeNewswire 1mo ago

AKBA
+2.46%
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2mo ago

AKBA
+2.46%
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

GlobeNewswire 2mo ago

AKBA
+2.46%
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire 3mo ago

AKBA
+2.46%
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

GlobeNewswire 4mo ago

AKBA
+2.46%
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 5mo ago

AKBA
+2.46%
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire 5mo ago

AKBA
+2.46%
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire 5mo ago

AKBA
+2.46%
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire 6mo ago

AKBA
+2.46%

U.S. markets closed

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights